Buy & Sell Occidental Petroleum Corporation (OXY) – Occidental Petroleum Corporation Price Today
Key Stats
- $56.25BMarket Cap
- EnergySector
- -19.94%3M Drawdown
- $77.33BEnterprise Value
- 1.84%Dividend Yield
- 18% Buy | 82% SellTrading Activity
- 84 daysTypical Hold Time
Occidental Petroleum Corporation (OXY) is currently valued at a market capitalization of $56.25B, with an enterprise value of $77.33B. Over the past 52 weeks, Occidental Petroleum Corporation has traded between a low of $38.92 and a high of $66.24, highlighting its annual price range. Over the past three months, Occidental Petroleum Corporation has recorded a drawdown of -19.94%, reflecting recent price volatility. Occidental Petroleum Corporation offers a dividend yield of 1.84%, with the most recent dividend of $0.26 paid on 10 Jun 26. On average, investors hold Occidental Petroleum Corporation for approximately 84 days, indicating typical investor behavior on the platform.
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Most Recent News
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...

Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...

Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...
